BDTX — Black Diamond Therapeutics Share Price
0.000.00%
Last trade - 00:00- $100.88m
- $2.31m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.21 | ||
| Price to Tang. Book | 1.21 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -77.19% | ||
| Return on Equity | -69.67% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 28 | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Directors
- Robert Ingram NEC
- David Epstein PRE (62)
- Fang Ni CFO
- Brent Hatzis-Schoch COO (56)
- Elizabeth Buck EVP (46)
- Karsten Witt SVP (64)
- Bradley Bolzon DRC (61)
- Kapil Dhingra DRC (61)
- Alexander Mayweg DRC (46)
- Ali Behbahani IND (44)
- Samarth Kulkarni IND (42)
- Garry Menzel IND (57)
- Rajeev Shah IND (43)
- Mark Velleca IND (57)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- December 29th, 2014
- Public Since
- January 30th, 2020
- No. of Shareholders
- 26
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 56,676,716
- Address
- One Main Street, 14Th Floor, CAMBRIDGE, 02142
- Web
- https://www.blackdiamondtherapeutics.com/
- Phone
- +1 6174175868
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for BDTX
Black Diamond Therapeutics Inc Annual Shareholders Meeting
Black Diamond Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Black Diamond Therapeutics Inc Earnings Release
Q3 2025 Black Diamond Therapeutics Inc Earnings Release
Similar to BDTX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Black Diamond Therapeutics share price?
As of Today at 19:37 UTC, shares in Black Diamond Therapeutics are trading at $1.78. This share price information is delayed by 15 minutes.
How has the Black Diamond Therapeutics share price performed this year?
Shares in Black Diamond Therapeutics last closed at $1.78 and the price had moved by -72.99% over the past 365 days. In terms of relative price strength the Black Diamond Therapeutics share price has underperformed the S&P500 Index by -75.64% over the past year.
What are the analyst and broker recommendations for Black Diamond Therapeutics?
The overall consensus recommendation for Black Diamond Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Black Diamond Therapeutics dividend yield?
Black Diamond Therapeutics does not currently pay a dividend.
Does Black Diamond Therapeutics pay a dividend?
Black Diamond Therapeutics does not currently pay a dividend.
When does Black Diamond Therapeutics next pay dividends?
Black Diamond Therapeutics does not currently pay a dividend.
How do I buy Black Diamond Therapeutics shares?
To buy shares in Black Diamond Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Black Diamond Therapeutics?
As of the previous close price of $1.78, shares in Black Diamond Therapeutics had a market capitalisation of $100.88m.
Where are Black Diamond Therapeutics shares listed?
Here are the trading details for Black Diamond Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: BDTX
What kind of share is Black Diamond Therapeutics?
Based on an overall assessment of its quality, value and momentum Black Diamond Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Black Diamond Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Black Diamond Therapeutics is $13.00. That is 630.34% above the last closing price of $1.78.
Analysts covering Black Diamond Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.55 for the next financial year.
Find out moreWhat is the trend in the Black Diamond Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Black Diamond Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -38.13%.
As of the last closing price of $1.78, shares in Black Diamond Therapeutics were trading -44.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Black Diamond Therapeutics PE Ratio?
The Black Diamond Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.78.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Black Diamond Therapeutics?
Black Diamond Therapeutics' management team is headed by:
- Robert Ingram - NEC
- David Epstein - PRE
- Fang Ni - CFO
- Brent Hatzis-Schoch - COO
- Elizabeth Buck - EVP
- Karsten Witt - SVP
- Bradley Bolzon - DRC
- Kapil Dhingra - DRC
- Alexander Mayweg - DRC
- Ali Behbahani - IND
- Samarth Kulkarni - IND
- Garry Menzel - IND
- Rajeev Shah - IND
- Mark Velleca - IND